A new drug to treat bladder and urinary tract cancers, developed by Yale Cancer Center and Smilow Cancer Hospital researchers, has been approved by the FDA.
Enfortumab vedotin, described as a “smart bomb” by the senior investigator in its clinical trial, was granted accelerated approval for treating adult patients with advanced urothelial or bladder cancer, after a clinical trial at multiple institutions.